Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 159-166

  Yoshida, Makoto ^a,b   Nakano, Takako ^a   Fukuyama, Satoru ^a   Matsumoto, Takafumi ^a   Eguchi, Miyuki ^a   Moriwaki, Atsushi ^a   Takata, Shohei ^a,b   Machida, Kentaro ^d   Kanaya, Akiko ^c   Matsumoto, Koichiro ^a   Nakanishi, Yoichi ^a   Inoue, Hiromasa ^a,d  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Bronchial asthma; Chronic obstructive pulmonary disease; Tiotropium

Indexed keywords

GLUCOCORTICOID; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG EMPHYSEMA; LUNG FUNCTION; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; SCOPOLAMINE DERIVATIVES; VITAL CAPACITY;

EID: 84874580397     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.09.007     Document Type: Article

References (23)

1. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004, 170:836-844.
2. Szefler S.J., Martin R.J., King T.S., Boushey H.A., Cherniack R.M., Chinchilli V.M., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 109:410-418.
3. Gross N.J. Anticholinergic agents in asthma and copd. Eur J Pharmacol 2006, 533:36-39.
4. Barnes P.J., Belvisi M.G., Mak J.C., Haddad E.B., O'Connor B. Tiotropium bromide (ba 679 br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995, 56:853-859.
5. van Noord J.A., Smeets J.J., Custers F.L., Korducki L., Cornelissen P.J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002, 19:639-644.
6. Global initiative for chronic obstructive lung disease (gold) home page. (). http://www.Goldcopd.Org/.
7. Peters S.P., Kunselman S.J., Icitovic N., Moore W.C., Pascual R., Ameredes B.T., et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363:1715-1726.
8. Bateman E.D., Kornmann O., Schmidt P., Pivovarova A., Engel M., Fabbri L.M. Tiotropium is noninferior to salmeterol in maintaining improved lung function in b16-arg/arg patients with asthma. J Allergy Clin Immunol 2011, 128:315-322.
9. Kerstjens H.A., Disse B., Schroder-Babo W., Bantje T.A., Gahlemann M., Sigmund R., et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011, 128:308-314.
10. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152:S77-S121. American thoracic society.
11. Boschetto P., Miniati M., Miotto D., Braccioni F., De Rosa E., Bononi I., et al. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir J 2003, 21:450-454.
12. Sakai F., Gamsu G., lrn J.-G., Ray C.S. Pulmonary function abnormalities in patients with CT-determined emphysema. J Comput Assist Tomogr 1987, 11:963-968.
13. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable copd. Respir Med 2004, 98:1214-1221.
14. Rodrigo G., Rodrigo C., Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999, 107:363-370.
15. COMBIVENT Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 105:1411-1419.
16. Smith L.J. Anticholinergics for patients with asthma?. N Engl J Med 2010, 363:1764-1765.
17. Gosens R., Zaagsma J., Meurs H., Halayko A.J. Muscarinic receptor signaling in the pathophysiology of asthma and copd. Respir Res 2006, 7:73.
18. Ikeda A., Nishimura K., Koyama H., Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable copd: comparison with ipratropium bromide alone. Chest 1995, 107:401-405.
19. Taube C., Kanniess F., Gronke L., Richter K., Mucke M., Paasch K., et al. Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with copd or asthma. Respir Med 2003, 97:568-577.
20. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
21. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
22. Gosens R., Bos I.S., Zaagsma J., Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005, 171:1096-1102.
23. Casaburi R., Briggs D.D., Donohue J.F., Serby C.W., Menjoge S.S., Witek T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable copd: a 13-week multicenter trial. The US tiotropium study group. Chest 2000, 118:1294-1302.